US Patent

US8759350 — Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders

Method of Use · Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2027-03-02 · 1y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition that combines a carbostyril derivative, such as aripiprazole, with a serotonin reuptake inhibitor for treating mood disorders.

USPTO Abstract

The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1529 — Abilify
U-1529 — Abilify
U-1529 — Abilify
U-1529 — Abilify
U-1529 — Abilify
U-1529 — Abilify
U-1529 — Abilify
U-1529 — Abilify
U-1529 — Abilify
U-1529 — Abilify
U-1529 — Abilify
U-1529 — Abilify
U-1529 — Abilify
U-1529 — Abilify
U-1529 — Abilify

Patent Metadata

Patent number
US8759350
Jurisdiction
US
Classification
Method of Use
Expires
2027-03-02
Drug substance claim
No
Drug product claim
No
Assignee
Otsuka Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.